New lease of life for asthmatics by Accentia Biopharmaceuticals
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), through its specialty pharmaceuticals subsidiary, TEAMM Pharmaceuticals, Inc., has developed MD Turbo.// It is the first and only available product that transforms many of the most commonly prescribed metered dose inhalers (MDIs) into breath-activated, dose-counting inhalers. MD Turbo will be available at pharmacies in May of this year....
Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 -
AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...
Accentia Biopharmaceuticals Scientific Presentations Demonstrate
Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at
the Annual Meeting of the American Academy of Allergy, Asthma, and
Immunology
TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 -
AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...